Epidemiology and pathophysiology of retinopathy of prematurity;Épidémiologie et physiopathologie de la rétinopathie du prématuré

Archives de Pediatrie

Volumn 18, Issue SUPPL. 2, 2011, Pages

  Kermorvant Duchemin, E ^a,b,c   Sennlaub, F ^b,d   Behar Cohen, F ^b,c,d   Chemtob, S ^e  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔTEL DIEU   (France)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN BINDING PROTEIN 3; VASCULOTROPIN;

ARTICLE; DISEASE ASSOCIATION; HUMAN; METABOLITE; NEWBORN HYPOXIA; PATHOPHYSIOLOGY; PROTEIN FUNCTION; RETINA DEGENERATION; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; SIGNAL TRANSDUCTION;

HUMANS; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR I; OXIDATIVE STRESS; OXYGEN INHALATION THERAPY; REACTIVE OXYGEN SPECIES; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960408021     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/S0929-693X(11)71095-8     Document Type: Article

References (50)

1. Lad E.M., Hernandez-Boussard T., Morton J.M., et al. Incidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol 2009, 148:451-458.
2. Good W.V., Hardy R.J., Dobson V., et al. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 2005, 116:15-23.
3. Costeloe K., Hennessy E., Gibson A., et al. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000, 106:659-671.
4. Allegaert K., de Coen K., Devlieger H., et al. Threshold retinopathy at threshold of viability: the EpiBel study. Br J Ophthalmol 2004, 88:239-242.
5. Fellman V., Hellström-Westas L., et al. One-year survival of extremely preterm infants after active perinatal care in Sweden. JAMA 2009, 301:2225-2233. EXPRESS group.
6. Gaugler C., Beladdale J., Astruc D., et al. Rétinopathie du pré maturé: étude rétrospective sur une période de dix ans au CHU de Strasbourg. Arch Pédiatr 2002, 9:350-357.
7. Beby F., Burillon C., Putet G., et al. Rétinopathie du prématuré: résultats de l'examen du fond d'oeil chez 94 enfants à risque. J Fr Ophtalmol 2004, 27:337-344.
8. Gilbert C., Fielder A., Gordillo L., et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005, 115:e518-e525.
9. Hughes S., Yang H., Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000, 41:1217-1228.
10. Chan-Ling T., Gock B., Stone J. The effect of oxygen on vasoformative cell division. Evidence that " physiological hypoxia" is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci 1995, 36:1201-1214.
11. Stone J., Itin A., Alon T., et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995, 15:4738-4747.
12. Carmeliet P., Ferreira V., Breier G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
13. Carlo W.A., Finer N.N., Walsh M.C, et al. Target ranges of oxygen saturation in extremely preterm infants. New Engl J Med 2010, 362:1959-1969. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network.
14. Hardy P., Dumont I., Bhattacharya M., et al. Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. Cardiovasc Res 2000, 47:489-509.
15. Chemtob S., Hardy P., Abran D., et al. Peroxide-cyclooxygenase interactions in postasphyxial changes in retinal and choroidal hemodynamics. J Appl Physiol 1995, 78:2039-2046.
16. Beauchamp M.H., Marrache A.M., Hou X., et al. Platelet-activating factor in vasoobliteration of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2002, 43:3327-3337.
17. Beauchamp M.H., Martinez-Bermudez A.K., Gobeil F., et al. Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy. J Appl Physiol 2001, 90:2279-2288.
18. Beauchamp M.H., Sennlaub F., Speranza G., et al. Redox-dependent effects of nitric oxide on microvascular integrity in oxygeninduced retinopathy. Free Radic Biol Med 2004, 37:1885-1894.
19. Holmes J.M., Zhang S., Leske D.A., et al. The effect of carbon dioxide on oxygen-induced retinopathy in the neonatal rat. Curr Eye Res 1997, 16:725-732.
20. Checchin D., Hou X., Hardy P., et al. PGE2-mediated eNOS induction in prolonged hypercapnia. Invest Ophthalmol Vis Sci 2002, 43:1558-1566.
21. Checchin D., Sennlaub F., Sirinyan M., et al. Hypercapnia prevents neovascularization via nitrative stress. Free Radic Biol Med 2006, 40:543-553.
22. Brooks S.E., Gu X., Samuel S., et al. Reduced severity of oxygeninduced retinopathy in eNOS-deficient mice. Invest Ophthalmol Vis Sci 2001, 42:222-228.
23. Kermorvant-Duchemin E., Sennlaub F., Sirinyan M., et al. Transarachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneration. Nat Med 2005, 11:1339-1345.
24. Wang S., Wu Z., Sorenson C.M., et al. Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn 2003, 228:630-642.
25. Arjamaa O., Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res 2006, 83:473-483.
26. Sears J.E., Hoppe G., Ebrahem Q., et al. Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy. Proc Natl Acad Sci U S A 2008, 105:19898-19903.
27. Alon T., Hemo I., Itin A., et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995, 1:1024-1028.
28. Pierce E.A., Foley E.D., Smith L.E. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity [erratum 1997, 115: 427]. Arch Ophthalmol 1996, 114:1219-1228.
29. Stone J., Chan-Ling T., Pe'er J., et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996, 37:290-299.
30. Shih S.C., Ju M., Liu N., et al. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest 2003, 112:50-57.
31. Chen J., Connor K.M., Aderman C.M., et al. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008, 118:526-533.
32. Chen J., Connor K.M., Aderman C.M., et al. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2009, 50:1329-1335.
33. Lineham J.D., Smith R.M., Dahlenburg G.W., et al. Circulating insulinlike growth factor I levels in newborn premature and full-term infants followed longitudinally. Early Hum Dev 1986, 13:37-46.
34. Hellstrom A., Perruzzi C., Ju M., et al. Low IGF-I suppresses VEGFsurvival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 2001, 98:5804-5808.
35. Smith L.E., Shen W., Perruzzi C., et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999, 5:1390-1395.
36. Hellstrom A., Engstrom E., Hard A.L., et al. Postnatal serum insulinlike growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003, 112:1016-1020.
37. Löfqvist C., Andersson E., Sigurdsson J., et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 2006, 124:1711-1718.
38. Hellström A., Hard A.L., Engström E., et al. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics 2009, 123:e638-e645.
39. Firth S.M., Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002, 23:824-854.
40. Lofqvist C., Chen J., Connor K.M., et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci U S A 2007, 104:10589-10594.
41. Pierce E.A., Avery R.L., Foley E.D., et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 1995, 92:905-909.
42. Aiello L.P., Pierce E.A., Foley E.D., et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995, 92:10457-10461.
43. Mintz-Hittner H.A., Kennedy K.A., Chuang A.Z. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New Engl J Med 2011, 364:603-615. BEAT-ROP Cooperative Group.
44. Smith L.E., Kopchick J.J., Chen W., et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997, 276:1706-1709.
45. Sapieha P., Sirinyan M., Hamel D., et al. The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat Med 2008, 14:1067-1076.
46. Mino R., Spoerri P., Caballero S., et al. Adenosine receptor antagonists and retinal neovascularization in vivo. Invest Ophthalmol Vis Sci 2001, 42:3320-3324.
47. Clandinin M.T., Chappell J.E., Leong S., et al. Intrauterine fatty acid accretion rates in human brain: implications for fatty acid requirements. Early Hum Dev 1980, 4:121-129.
48. SanGiovanni J.P., Chew E.Y. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 2005, 24:87-138.
49. Connor K.M., SanGiovanni J.P., Lofqvist C., et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007, 13:868-873.
50. Sennlaub F., Valamanesh F., Vazquez-Tello A., et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 2003, 108:198-204.